Antitrust issues are complex by nature, combining the threat of regulatory scrutiny and potential criminal prosecution with private civil litigation. They can involve multiple governmental agencies in the U.S. and abroad, as well as numerous private parties. Our team defuses antitrust threats with a combination of litigation brilliance, the strong business acumen of seasoned commercial litigators and the credibility possessed by, among others, former top U.S. Federal Trade Commission and U.S. Department of Justice regulators.

Landmark Antitrust Victory for Becton Dickinson in the Fifth Circuit

Paul, Weiss secured a significant antitrust appellate victory for global medical technology company Becton Dickinson & Company (BD).

» more

Increased Scrutiny for Technology Companies

Recent government reports and statements from politicians signal a shift toward increased scrutiny of large technology companies for potential monopolization violations.

» more

Elanco to Acquire Boehringer Ingelheim Vetmedica’s Vaccines Portfolio

As reported in The Wall Street JournalBloombergReuters and other media outlets, Paul, Weiss client Elanco U.S., Inc., a subsidiary of Paul, Weiss client Eli Lilly and Company, announced an agreement to acquire Boehringer Ingelheim Vetmedica, Inc.'s U.S. feline, canine and rabies vaccines portfolio, as well as a fully integrated manufacturing and R&D site, for $885 million. 

» more

Benchmark Litigation Names Paul, Weiss “Antitrust Firm of the Year”

Paul, Weiss has been named Benchmark Litigation's "Antitrust Firm of the Year" for 2015. Litigation partners Aidan Synnott, Jacqueline Rubin and William Michael received the award for the firm on January 29 at the Essex House in New York at the second annual nationwide U.S. Benchmark Litigation Awards ceremony.

» more

Infront Sports & Media Wins Dismissal of Class Action Suit

Judge James C. Mahan of the District of Nevada granted Paul, Weiss client Infront Sports & Media AG's motion to dismiss a putative class action brought by two Nevada residents against Infront and five other defendants, including Fédération Internationale de Football Association (FIFA).

» more

Nichi-Iko Pharmaceutical to Acquire Sagent Pharmaceuticals

Paul, Weiss client Nichi-Iko Pharmaceutical Co., Ltd., the largest generic drug manufacturer in Japan by sales, announced that it has agreed to acquire Sagent Pharmaceuticals, Inc. in an all-cash tender offer followed by a second-step cash merger, for a total consideration of approximately $736 million.

» more

Time Warner Cable Completes Merger With Charter Communications

Paul, Weiss represented Time Warner Cable Inc. in its completed merger with Charter Communications, Inc. As a result of the merger, Charter and Time Warner Cable have both become wholly owned subsidiaries of a new, publicly traded company, which will continue under the name Charter Communications, Inc.

» more

© 2017 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy